Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ampyra in SMA Type 3
NCT01645787Phase 3Completed
- Sponsor
- Columbia University
- Start
- Jun 2012
- Primary completion
- Sep 2015
- Countries
- 1
01
Overview
A Phase 3 trial of dalfampridine in Spinal muscular atrophy type 3 (SMA3), sponsored by Columbia University. Started Jun 2012; status: completed.
02
Drugs
dalfampridine
03
Conditions
Spinal muscular atrophy type 3 (SMA3)
Beyond the preview
Go deeper on NCT01645787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01645787.